Biocon eyes specialty build-up, insulin disposable devices foray

Biocon has reported a 15% increase in revenues to INR8.54bn ($134.8m) for the fourth quarter ended March 2015, backed by the strong showing of its IPO-bound research services subsidiary, Syngene, and a 12% growth in its biopharma business.